The Johnson & Johnson single-dose vaccine against COVID-19 was shown to be safe and effective in the trials, said the staff of the United States Drug Administration (FDA) in documents published Wednesday.

An assessment that paves the way for your next approval for pandemic emergency use.

The

FDA's

panel of independent experts

meets Friday to decide whether to approve this formula

.

While it is not required to follow the advice of its experts, the FDA did do so previously when licensing the Pfizer and Moderna vaccines.

The vaccine made by J&J subsidiary Janssen was 66% effective in preventing Covid-19 against multiple variants in a global trial that involved nearly 44,000 people, the company said last month.

That effectiveness ranged from 72% in the United States to 66% in Latin America and 57% in South Africa, where a new variant has spread.

However, the vaccine was

85% effective overall in stopping severe cases of the disease

.

The vaccine was effective in reducing the risk of COVID-19 and preventing PCR-confirmed COVID-19 for at least 14 days after vaccination, the FDA states in its information documents.

Three vaccine recipients had

serious

side

effects in the trial, but the US agency said its analysis did not raise any specific safety concerns that would prevent the issuance of an emergency use authorization.

Johnson & Johnson had so far not released details about its clinical trials beyond efficacy rates.

According to the criteria of The Trust Project

Know more

  • Covid 19

  • Coronavirus

Coronavirus The new tamper cameras at Hospital Isabel Zendal: "Very strange things happen here, it is an orchestrated plan"

CoronavirusA teenager wakes up from an 11-month coma unaware of the Covid-19 pandemic

Catalonia elections 2021The struggle of Ciudadanos, PP and Vox for the reduced space of the non-independence right in Gerona

See links of interest

  • Work calendar

  • Lazio - FC Bayern München

  • Atlético - Chelsea, live